

University of Groningen

From presentation to paper

Dijksterhuis, Willemieke P. M.; Stroes, Charlotte; Tan, Wan-Ling; Ithimakin, Suthinee; Calles, Antonio; van Oijen, Martijn G. H.; Verhoeven, Rob H. A.; Barriuso, Jorge; Oosting, Sjoukje F.; Ivankovic, Daniela Kolarevic

Published in:
International Journal of Cancer

DOI:
[10.1002/ijc.32660](https://doi.org/10.1002/ijc.32660)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Dijksterhuis, W. P. M., Stroes, C., Tan, W-L., Ithimakin, S., Calles, A., van Oijen, M. G. H., Verhoeven, R. H. A., Barriuso, J., Oosting, S. F., Ivankovic, D. K., Furness, A. J. S., Bozovic-Spasojevic, I., Gomez-Roca, C., & van Laarhoven, H. W. M. (2020). From presentation to paper: Gender disparities in oncological research. *International Journal of Cancer*, 37(15). <https://doi.org/10.1002/ijc.32660>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

From presentation to paper: Gender disparities in oncological research

Willemieke P.M. Dijksterhuis^{1,2}, Charlotte I. Stroes¹, Wan-Ling Tan³, Suthinee Ithimakin⁴, Antonio Calles⁵, Martijn G.H. van Oijen^{1,2}, Rob H.A. Verhoeven², Jorge Barriuso^{6,7}, Sjoukje F. Oosting⁸, Daniela Kolarevic Ivankovic⁹, Andrew J.S. Furness⁹, Ivana Bozovic-Spasojevic¹⁰, Carlos Gomez-Roca¹¹ and Hanneke W.M. van Laarhoven¹

¹Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

²Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands

³Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore

⁴Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

⁵Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

⁶Division of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester, United Kingdom

⁷Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom

⁸Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

⁹The Royal Marsden NHS Foundation Trust, London, United Kingdom

¹⁰Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

¹¹Institut Universitaire du Cancer de Toulouse (IUCT), Toulouse, France

Gender disparities in scientific publications have been identified in oncological research. Oral research presentations at major conferences enhance visibility of presenters. The share of women presenting at such podiums is unknown. We aim to identify gender-based differences in contributions to presentations at two major oncological conferences. Abstracts presented at plenary sessions of the American Society of Clinical Oncology (ASCO) Annual Meetings and European Society for Medical Oncology (ESMO) Congresses were collected. Trend analyses were used to analyze female contribution over time. The association between presenter's sex, study outcome (positive/negative) and journals' impact factors (IFs) of subsequently published papers was assessed using Chi-square and Mann-Whitney *U* tests. Of 166 consecutive abstracts presented at ASCO in 2011–2018 ($n = 34$) and ESMO in 2008–2018 ($n = 132$), 21% had female presenters, all originating from Northern America ($n = 17$) or Europe ($n = 18$). The distribution of presenter's sex was similar over time ($p = 0.70$). Of 2,425 contributing authors to these presented abstracts, 28% were women. The proportion of female abstract authors increased over time ($p < 0.05$) and was higher in abstracts with female (34%) compared to male presenters (26%; $p < 0.01$). Presenter's sex was not associated with study outcome ($p = 0.82$). Median journals' IFs were lower in papers with a female first author ($p < 0.05$). In conclusion,

Additional Supporting Information may be found in the online version of this article.

Key words: research, medical oncology, sex, Congresses as topic

Conflict of interest: A.C. reports honorary/consulting fees from AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche/Genentech, Eli Lilly and Company, Novartis, Merck Sharp & Dohme and Bristol-Myers Squibb, outside the submitted work. J.B. reports grants and nonfinancial support from AAA, EISAI, Ipsen, Novartis and Nanostring, and personal fees and nonfinancial support from Pfizer, outside the submitted work. S.F.O. reports grants from Celldex and Novartis, outside the submitted work. M.G.H.v.O. has received unrestricted research grants from BMS, Merck Serono, Nordic, Roche and Servier, outside the submitted work. R.H.A.V. has received unrestricted research grants from BMS and Roche, outside the submitted work. H.W.M.v.L. has served as a consultant for BMS, Celgene, Lilly and Nordic and has received unrestricted research funding from Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, Philips and Roche, outside the submitted work. The other authors have nothing to disclose.

Part of our study was presented at ASCO Annual Meeting 2019, Chicago, IL.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1002/ijc.32660

History: Received 7 Jun 2019; Accepted 7 Aug 2019; Online 31 Aug 2019

Correspondence to: Hanneke W.M. van Laarhoven, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands, Tel.: +31-20-5665955, Fax: +31-20-6919743, E-mail: h.vanlaarhoven@amsterdamumc.nl

there is a clear gender disparity in research presentations at two major oncological conferences, with 28% of authors and 21% of presenters of these studies being female. Lack of visibility of female presenters could impair acknowledgement for their research, opportunities in their academic career and even hamper heterogeneity in research.

What's new?

Presenting one's research at a conference is a great way to get your name and ideas heard within the professional community. In this study, the authors investigated how often women served as presenters at plenary sessions of ASCO Annual Meetings and ESMO Congresses. Looking through 166 abstracts over a period of 8 years, they found that 21% had female presenters, while 28% of study authors were female. Lack of visibility for female researchers at conferences can slow their career progress, and greater representation should be encouraged.

Introduction

Gender inequalities in science and medicine are increasingly brought to the fore. Despite an expanding number of women entering the field of medicine, female physicians are still at disadvantage in obtaining jobs, less rewarded than men and underrepresented in leadership positions.^{1–5} In medical research, gender differences are even more pronounced: women are less likely to hold first-author positions on top publications, receive requested grants, be invited as a peer reviewer, or become a full professor.^{1,4–7}

Gender discrepancies in authorships of scientific publications have been identified in many disciplines all over the world, including oncology.^{2,8–12} However, results of a clinical research project are often first brought to life through a presentation at an international conference. Such a presentation gives the scientific study an actual identity through visibility of the researcher. Presentations at major international conferences are not only important for discussion of the outcomes of a study, they also provide the presenter the opportunity for recognition for as a principal investigator, and increase the chance of climbing the academic career ladder.

Female underrepresentation in presenting studies and invitation to speak at conferences has been identified in other disciplines.^{13–18} The exact share of women presenting at major oncological conferences is not clear. In our study, we aimed to identify potential gender-based differences in contributions to presentations at two major international oncological conferences: the American Society of Clinical Oncology (ASCO) Annual Meetings and European Society for Medical Oncology (ESMO) Congresses.

Methods

Data collection

We aimed to collect consecutive abstracts of all plenary sessions of ASCO Annual Meetings and presidential sessions of ESMO Congresses between 2000 and 2018. The abstracts presented at these sessions are assumed to have the highest impact on oncological research and practice. Specific data on ASCO abstracts were available from 2011 and on ESMO abstracts from 2008.

Data on ASCO abstracts, including sexes of the presenters, were provided by ASCO Center for Research and Analytics for all abstracts presented at the plenary sessions since 2011. All consecutive ESMO abstracts presented at the presidential sessions since 2008 were identified from the ESMO website (www.esmo.org) or the website of the conference. Data extracted from the abstracts included information on presenters, names and order of authors, country of origin, study subject and results. Sexes of presenters and authors were interpreted based on their first names or, if inconclusive, based on available online information including photos and electronic portfolio of the specific author. Study results were defined as positive and negative if they met or did not meet the primary endpoints, respectively, and neither negative nor positive if results were not clear yet, or if both positive and negative results were found.

From all abstracts, the subsequently published papers were identified and corresponding impact factors (IFs) of the journals in which they were published (obtained from InCites Journal Citation Reports) were collected. One-year IFs of the year in which the article was published were used, or of the previous year in case IFs were not yet known. Any changes in authorships compared to the presented abstract were identified.

Ethical approval to perform our study was not considered to be necessary.

Statistical analysis

Descriptive statistics were used to display the distribution of presenter's and abstract author's sex. Chi-square or Fisher's exact tests where appropriate were used to compare the sex distribution in abstract presenters and authors per year. The association between presenter's or last author's sex and distribution of author's sex, study outcome and IFs were analyzed using Chi-square and Mann-Whitney *U* tests, respectively. A trend in contribution of both sexes in presenters and abstract authors over time was tested using the Cochran-Armitage trend test; *p*-values lower than 0.05 were regarded as statistically significant. Statistical analyses were performed using SAS software (version 9.4, SAS institute, Cary, NC).

Table 1. Abstracts presented at ASCO annual meetings

Presenter			Abstract			Article											
Year	Abstract no.	Name	Sex	Country of origin	Author place	Sex last presenter	No. of authors	No. of male authors	No. of female authors	No. of authors unknown sex	Study outcome ¹	Journal published	Year	IF	Sex of the first author	Sex of the last author	Subject
2011	A-2011-1 ⁴¹	H. Joensuu	M	Finland	First	M	18	13	5	0	P	JAMA J Am Med Assoc ⁴²	2012	29.978	M	M	GIST
	A-2011-2 ⁴³	R.L. Ladenstein	F	Austria	First	F	19	9	10	0	P	Lancet Oncol ⁴⁴	2017	36.418	F	F	Neuroblastoma
	A-2011-3 ⁴⁵	E.C. Larsen	M	United States	First	M	16	8	8	0	P	J Clin Oncol ⁴⁶	2016	24.008	M	M	Leukemia
	A-2011-4 ⁴⁷	P.B. Chapman	M	United States	First	M	20	17	3	0	P	New Engl J Med ⁴⁸	2011	53.298	M	M	Melanoma
2012	A-2011-5 ⁴⁹	J.D. Wolchok	M	United States	First	F	10	9	1	0	P	New Engl J Med ⁵⁰	2011	53.298	F	M	Melanoma
	A-2012-1 ⁵¹	K.L. Blackwell	F	United States	First	M	14	10	4	0	P	New Engl J Med ⁵²	2012	51.658	M	F	Breast cancer
	A-2012-2 ⁵³	M.J. Van Den Bent	M	The Netherlands	First	M	19	15	4	0	P	J Clin Oncol ⁵⁴	2013	17.879	M	M	Oligodendroglioma
	A-2012-3 ⁵⁵	M.J. Rummel	M	Germany	First	M	18	15	3	0	P	Lancet ⁵⁶	2013	39.207	M	M	Lymphoma
2013	A-2012-4 ⁵⁷	M. Hussain	F	United States	First	M	18	13	5	0	N	New Engl J Med ⁵⁸	2013	54.420	F	M	Prostate cancer
	A-2013-1 ⁵⁹	M.R. Gilbert	M	United States	First	M	20	15	5	0	N	New Engl J Med ⁶⁰	2014	55.873	M	M	Glioblastoma
	A-2013-2 ⁶¹	S.S. Shastri	M	India	First	M	6	4	2	0	P	JNCI J Natl Cancer ⁶²	2014	12.583	M	M	Cervical cancer
	A-2013-3 ⁶³	K.S. Tewari	M	United States	First	M	10	6	4	0	P	New Engl J Med ⁶⁴	2014	55.873	M	M	Cervical cancer
	A-2013-4 ⁶⁵	M.S. Brose	F	United States	First	M	16	12	4	0	P	Lancet ⁶⁶	2014	45.217	F	M	Thyroid cancer
	A-2013-5 ⁶⁷	R.G. Gray	M	United Kingdom	First	M	22	15	7	0	P	Not (yet) published					Breast cancer
	A-2014-1 ⁶⁸	O. Pagani	F	Switzerland	First	F	20	10	10	0	P	New Engl J Med ⁶⁹	2014	55.873	F	F	Breast cancer
	A-2014-2 ⁷⁰	C. Sweeney	M	United States	First	M	17	15	2	0	P	New Engl J Med ⁷¹	2015	59.558	M	M	Prostate cancer
2015	A-2014-3 ⁷²	A.P. Venook	M	United States	First	M	15	11	4	0	N	JAMA J Am Med Assoc ⁷³	2017	47.661	M	M	Colorectal cancer
	A-2014-4 ⁷⁴	M.J. Piccart	F	Belgium	First	F	20	15	5	0	N/P	Not (yet) published					Breast cancer
	A-2015-1 ⁷⁵	J.D. Wolchok	M	United States	First	M	20	17	3	0	P	New Engl J Med ⁷⁶	2015	59.558	M	M	Melanoma
	A-2015-2 ⁷⁷	G.T. Armstrong	M	United States	First	M	15	9	6	0	P	New Engl J Med ⁷⁸	2016	72.406	M	M	Childhood cancers
	A-2015-3 ⁷⁹	A. D'Cruz	M	India	First	M	16	6	10	0	P	New Engl J Med ⁸⁰	2015	59.558	M	M	Oral cancer
	A-2015-4 ⁸¹	P.D. Brown	M	United States	First	M	17	10	7	0	N	JAMA J Am Med Assoc ⁸²	2016	44.405	M	M	Multiple types of cancer
	A-2016-1 ⁸³	P.E. Goss	M	United States	First	F	20	11	9	0	P	New Engl J Med ⁸⁴	2016	72.406	M	F	Breast cancer
	A-2016-2 ⁸⁵	J.R. Perry	M	Canada	First	M	20	16	4	0	P	New Engl J Med ⁸⁶	2017	79.260	M	M	Glioblastoma
2017	A-2016-3 ⁸⁷	J.R. Park	F	United States	First	F	17	7	10	0	P	Not (yet) published					Neuroblastoma
	A-2016-4 ⁸⁸	A. Palumbo	M	Italy	First	M	19	13	5	1	P	New Engl J Med ⁸⁹	2016	72.406	M	M	Multiple myeloma
	A-2017-1 ⁹⁰	Q. Shi	F	United States	First	M	20	16	4	0	N/P	New Engl J Med ⁹¹	2018	70.670	M	M	Colorectal cancer
	A-2017-2 ⁹²	E.M. Basch	M	United States	First	F	13	6	7	0	P	JAMA J Am Med Assoc ⁹³	2017	47.661	M	F	Multiple types of cancer
	A-2017-3 ⁹⁴	K. Fizazi	M	France	First	M	15	11	3	1	P	New Engl J Med ⁹⁵	2017	79.260	M	M	Prostate cancer
	A-2017-4 ⁹⁶	M.E. Robson	M	United States	First	M	14	6	8	0	P	New Engl J Med ⁹⁷	2017	79.260	M	M	Breast cancer
	A-2018-1 ⁹⁸	J.A. Sparano	M	United States	First	M	20	14	6	0	P	New Engl J Med ⁹⁹	2018	70.670	M	M	Breast cancer
	A-2018-2 ¹⁰⁰	G. Bisogno	M	Italy	First	M	12	6	6	0	P	Lancet Oncol ¹⁰¹	2018	35.386	M	M	Rhabdomyosarcoma
2018	A-2018-3 ¹⁰²	A. Mejean	M	France	First	M	20	18	2	0	P	New Engl J Med ¹⁰³	2018	70.670	M	M	Renal cell carcinoma
	A-2018-4 ¹⁰⁴	G. Lopes	M	United States	First	M	13	10	2	1	P	Lancet ¹⁰⁵	2019	59.102	M	M	Lung cancer
Total	N = 34		F: N = 8			F: N = 7	569	388	178	3	N = 31				F: N = 5	F: N = 5	

¹Abstracts presented at plenary sessions of ASCO annual meetings between 2011 and 2018. For papers published in 2019, journal IFs of 2018 were used.

Abbreviations: ASCO, American Society of Clinical Oncology; F, female; GIST, gastrointestinal stroma cell tumor; IF, impact factor; M, male; N, negative; N/P, outcome did not reach significance or endpoint, but did show improvement/benefit or reached some of the outcomes; no., number; P, positive.

Table 2. abstracts presented at ESMO congresses

Presenter			Abstract			Article											
Year	Abstract no.	Name	Country	Sex of origin	Author place	Sex of the last author	No. of authors	No. of male authors	No. of female authors	No. of authors unknown sex	Study outcome ¹	Journal published	Year	IF	Sex of the first author	Sex of the last author	Subject
2008	E-2008-1 ¹⁰⁶	C. Manegold	M	Germany	First	M	10	6	4	0	P	J Clin Oncol ¹⁰⁷	2009	17.793	M	M	Lung cancer
	E-2008-2 ¹⁰⁸	T. Mok	M	Hong Kong	First	M	10	6	4	0	P	New Engl J Med ¹⁰⁹	2009	47.050	M	M	Lung cancer
	E-2008-3 ¹¹⁰	R.S.J. Midgley	F	United Kingdom	First	M	10	5	5	0	N	J Clin Oncol ¹¹¹	2010	18.970	F	M	Colorectal cancer
	E-2008-4 ¹¹²	B.J. Monk	M	United States	First	M	10	8	2	0	P	J Clin Oncol ¹¹³	2010	18.970	M	F	Ovarian cancer
	E-2008-5 ¹¹⁴	S. Lee	M	United Kingdom	First	F	5	1	4	0	N	J Clin Oncol ¹¹⁵	2010	18.970	M	M	Glioma
	E-2008-6 ¹¹⁶	C. Karapetis	M	Australia	First	M	10	7	3	0	P	New Engl J Med ¹¹⁷	2008	50.017	M	M	Colorectal cancer
	E-2008-7 ¹¹⁸	M. Löhr	M	Germany	First	M	10	9	1	0	P	Ann Oncol ¹¹⁹	2012	7.384	M	M	Pancreatic cancer
	E-2008-8 ¹²⁰	P.M. Patel	M	United Kingdom	First	M	10	6	4	0	N	Eur J Cancer ¹²¹	2011	5.536	M	M	Melanoma
	E-2008-9 ¹²²	M. Auerbach	M	United States	First	M	8	6	2	0	P	Am J Hematol ¹²³	2010	3.576	M	M	Multiple types of cancer
	E-2009-1 ¹²⁴	M. van Hemelrijck	F	United Kingdom	First	M	8	6	2	0	P	J Clin Oncol ¹²⁵	2010	18.970	F	M	Prostate cancer
2009	E-2009-2 ¹²⁶	C. van de Velde	M	The Netherlands	First	M	10	8	2	0	P	Lancet ¹²⁷	2011	38.278	M	M	Breast cancer
	E-2009-3 ¹²⁸	A. M. Brunt	M	United Kingdom	First	M	10	6	4	0	P	Radiother Oncol ¹²⁹	2011	5.580	N/A	N/A	Breast cancer
	E-2009-4 ¹³⁰	R. Issels	M	Germany	First	M	10	10	0	0	P	Lancet Oncol ¹³¹	2010	17.764	M	M	Soft-tissue sarcoma
	E-2009-5 ¹³²	A. Stopeck	F	United States	First	F	10	5	5	0	P	J Clin Oncol ¹³³	2010	18.970	M	F	Breast cancer
	E-2009-6 ¹³⁴	M.E.L. van der Burg	F	The Netherlands	First	M	2	1	1	0	N	Lancet ¹³⁵	2010	33.633	M	F	Ovarian cancer
	E-2009-7 ¹³⁶	G.G. Steger	M	Germany	First	M	10	8	2	0	P	Ann Oncol ¹³⁷	2014	7.040	M	M	Breast cancer
	E-2009-8 ¹³⁸	J. Baseлга	M	Spain	First	M	10	8	2	0	P	J Clin Oncol ¹³⁹	2012	18.038	M	M	Breast cancer
	E-2009-9 ¹⁴⁰	M. Baumann	M	Germany	First	M	10	8	2	0	N/P	Radiother Oncol ¹⁴¹	2011	5.580	M	M	Lung cancer
	E-2009-10 ¹⁴²	D. Hailer	M	United States	First	M	10	9	1	0	P	J Clin Oncol ¹⁴³	2015	20.982	M	M	Colorectal cancer
	E-2009-11 ¹⁴⁴	T. Maughan	M	United Kingdom	First	M	10	9	1	0	N	Lancet ¹⁴⁵	2011	38.278	M	M	Colorectal cancer
2010	E-2009-12 ¹⁴⁶	S. Badve	M	United States	First	M	10	7	3	0	P	Not (yet) published					Breast cancer
	E-2009-13 ¹⁴⁷	P. Chapman	M	United States	First	M	10	10	0	0	P	New Engl J Med ¹⁴⁸	2010	53.486	M	M	Melanoma
	E-2009-14 ¹⁴⁹	B. Johnson	M	United States	First	M	7	6	1	0	P	J Clin Oncol ¹⁵⁰	2013	17.879	M	M	Lung cancer
	E-2009-15 ¹⁵¹	A. Inoue	M	Japan	First	M	10	10	0	0	P	Ann Oncol ¹⁵²	2013	6.578	M	M	Lung cancer
	E-2009-16 ¹⁵³	J. Douillard	M	France	First	F	10	9	1	0	P	J Clin Oncol ¹⁵⁴	2010	18.970	M	F	Colorectal cancer
	E-2009-17 ¹⁵⁵	C. Osborne	F	United States	Second	M	10	6	4	0	P	New Engl J Med ¹⁵⁶	2011	53.298	F	M	Breast cancer
	E-2009-18 ¹⁵⁷	A. Dueñas-González	M	Mexico	First	M	11	8	3	0	P	J Clin Oncol ¹⁵⁸	2011	18.372	M	M	Cervical cancer
	E-2009-19 ¹⁵⁹	E. van Cutsem	M	Belgium	First	M	10	7	3	0	P	Lancet ¹⁶⁰	2010	33.633	M	M	Gastric cancer
	E-2009-20 ¹⁶¹	C. Nutting	M	United Kingdom	First	F	10	8	2	0	P	Lancet Oncol ¹⁶²	2011	22.589	M	F	Head and neck cancer
	E-2009-21 ¹⁶³	A.M.M. Eggermont	M	The Netherlands	First	M	5	4	1	0	P	Eur J Cancer ¹⁶⁴	2012	5.061	M	M	Melanoma
2010	E-2009-22 ¹⁶⁵	E.L. Kwak	F	United States	First	M	10	9	1	0	P	Not (yet) published					Multiple types of cancer
	E-2010-1 ¹⁶⁶	V.A. Miller	M	United States	First	M	10	8	2	0	N/P	Lancet Oncol ¹⁶⁷	2012	23.117	M	M	Lung cancer
	E-2010-2 ¹⁶⁸	J. Chih-Hsin Yang	M	Taiwan	First	M	10	7	3	0	N	J Clin Oncol ¹⁶⁹	2011	18.372	M	M	Lung cancer
	E-2010-3 ¹⁷⁰	E.A. Perez	F	United States	First	F	10	5	5	0	P	Breast Cancer Res ¹⁷¹	2014	5.490	F	M	Breast cancer
	E-2010-4 ¹⁷²	T.J. Perren	M	United Kingdom	First	M	10	9	1	0	P	New Engl J Med ¹⁷³	2011	53.298	M	M	Ovarian cancer
2011	E-2010-5 ¹⁷⁴	J.S. De Bono	M	United Kingdom	First	M	10	10	0	0	P	New Engl J Med ¹⁷⁵	2011	53.298	M	M	Prostate cancer
	E-2011-1 ¹⁷⁶	L. Dirix	M	Belgium	First	M	9	7	1	1	P	New Engl J Med ¹⁷⁷	2012	51.658	M	M	Basal cell carcinoma
	E-2011-2 ¹⁷⁸	C. Parker	M	United Kingdom	First	M	10	9	1	0	P	New Engl J Med ¹⁷⁹	2013	54.420	M	M	Prostate cancer

(Continues)

Table 2. abstracts presented at ESMO congresses (Continued)

Presenter			Abstract			Article											
Year	Abstract no.	Name	Sex	Country of origin	Author place presenter	Sex of the last author	No. of authors	No. of male authors	No. of female authors	No. of unknown sex	Study outcome ¹	Journal published	Year	IF	Sex of the first author	Sex of the last author	Subject
2012	E-2011-3 ¹⁸⁰	J. Bourhis	M	Switzerland	First	F	17	15	2	0	N	Lancet Oncol ¹⁸¹	2012	25.117	M	F	Head and neck cancer
	E-2011-4 ¹⁸²	M. Bebin	F	United Kigdom	First	M	10	7	3	0	P	Lancet ¹⁸³	2013	39.207	M	M	Astrocytoma
	E-2011-5 ¹⁸⁴	I. Fernando	M	United Kingdom	First	M	10	8	2	0	P	Not (yet) published					Breast cancer
	E-2011-6 ¹⁸⁵	J. Tabernero	M	Spain	First	F	12	9	3	0	P	Eur J Cancer ¹⁸⁶	2014	5.417	M	F	Colorectal cancer
	E-2011-7 ¹⁸⁷	C. Aghajanian	F	United States	First	F	9	2	7	0	P	J Clin Oncol ¹⁸⁸	2012	18.038	F	M	Ovarian cancer
	E-2011-8 ¹⁸⁹	P. Hoskin	M	United Kingdom	First	M	13	9	4	0	N	JNCI J Natl Cancer ¹⁹⁰	2015	11.370	M	M	Prostate cancer
	E-2011-9 ¹⁹¹	R. Sullivan	M	United Kingdom	First	M	10	10	0	0	N/A	Lancet Oncol ¹⁹²	2011	22.589	M	M	Multiple types of cancer
	E-2011-10 ¹⁹³	L. Krug	M	United States	First	M	10	9	1	0	N	Lancet Oncol ¹⁹⁴	2015	26.509	M	M	Mesothelioma
	E-2011-11 ¹⁹⁵	J. Baselga	M	United States	First	M	10	8	2	0	P	Ann Oncol ¹⁹⁶	2014	7.040	F	M	Breast cancer
	E-2011-12 ¹⁹⁷	E.J.T. Rutgers	M	The Netherlands	Last	M (= presenter)	16	9	7	0	P	Eur J Cancer ¹⁹⁸	2011	5.536	M	F	Breast cancer
2013	E-2011-13 ¹⁹⁹	H.J. Bonjer	M	The Netherlands	First	M	7	6	1	0	P	New Engl J Med ²⁰⁰	2015	59.558	M	F	Colorectal cancer
	E-2011-14 ²⁰¹	M. Van Hemelrijck	F	United Kingdom	First	M	7	4	3	0	P	Hypertension ²⁰²	2012	6.873	F	F	Multiple types of cancer
	E-2011-15 ²⁰³	F. Amant	M	Belgium	First	F	16	9	7	0	N/P	Lancet Oncol ²⁰⁴	2012	25.117	M	F	Multiple types of cancer
	E-2011-16 ²⁰⁵	E. Papaemmanuil	F	United Kingdom	First	M	10	7	3	0	P	New Engl J Med ²⁰⁶	2011	53.298	F	M	Myelodysplastic malignancies
	E-2011-17 ²⁰⁷	M. Middleton	M	United Kingdom	First	M	10	9	1	0	N/P	Ann Oncol ²⁰⁸	2015	9.269	M	M	Melanoma
	E-2011-18 ²⁰⁹	E. van Cutsem	M	Belgium	First	M	11	9	2	0	P	Ann Oncol ²¹⁰	2015	9.269	M	M	Colorectal cancer
	E-2012-2 ²¹¹	A. Shaw	F	United States	First	M	20	14	6	0	P	New Engl J Med ²¹²	2013	54.420	F	M	Lung cancer
	E-2012-2 ²¹³	A.X. Zhu	M	United States	First	M	14	13	1	0	N	J Clin Oncol ²¹⁴	2015	20.982	M	M	Hepatocellular carcinoma
	E-2012-3 ²¹⁵	F. Lordick	M	Germany	First	M	16	12	4	0	N	Lancet Oncol ²¹⁶	2013	24.725	M	M	Gastric cancer
	E-2012-4 ²¹⁷	J. Taieb	M	France	First	M	19	16	3	0	N	Lancet Oncol ²¹⁸	2014	24.690	M	M	Colorectal cancer
2013	E-2012-5 ²¹⁹	X. Pivot	M	France	First	M	19	14	5	0	N	Lancet Oncol ²²⁰	2013	24.725	M	M	Breast cancer
	E-2012-6 ²²¹	R. Gelber	M	United States	Second	M	24	19	5	0	N	Lancet ²²²	2013	39.207	M	M	Breast cancer
	E-2012-7 ²²³	W. Van der Graaf	F	The Netherlands	Last	F (= presenter)	19	15	4	0	N	Lancet Oncol ²²⁴	2014	24.690	M	F	Soft-tissue sarcoma
	E-2012-8 ²²⁵	R.J. Motzer	M	United States	First	M	25	18	7	0	P	New Engl J Med ²²⁶	2013	54.420	M	M	Renal cell carcinoma
	E-2013-1 ²²⁷	P. Autier	M	France	First	M	4	3	1	0	N	Lancet Diabetes Endocrinol ²²⁸	2014	9.185	M	M	Multiple types of cancer
	E-2013-2 ²²⁹	P. Poortmans	M	The Netherlands	First	M	10	7	3	0	P	New Engl J Med ²³⁰	2015	59.558	M	M	Breast cancer
	E-2013-3 ²³¹	A.J. Breugnot	F	The Netherlands	First	M	11	7	4	0	N	Lancet Oncol ²³²	2015	26.509	F	M	Colorectal cancer
	E-2013-4 ²³³	M. Reimers	F	The Netherlands	First	M	10	7	3	0	P	JNCI J Natl Cancer ²³⁴	2014	12.583	F	M	Colorectal cancer
	E-2013-5 ²³⁵	G. Giaccone	M	United States	First	M	10	7	3	0	N/P	Eur J Cancer ²³⁶	2015	6.163	M	M	Lung cancer
	E-2013-6 ²³⁷	P. Ruszniewski	M	France	Second	F	13	7	6	0	P	New Engl J Med ²³⁸	2014	55.873	F	M	Neuroendocrine tumors
2013	E-2013-7 ²³⁹	P. Brastianos	F	United States	First	M	10	8	2	0	P	Cancer Discov ²⁴⁰	2015	19.783	F	M	Multiple types of cancer
	E-2013-8 ²⁴¹	P. Witteveen	F	The Netherlands	First	M	10	7	3	0	N	J Clin Oncol ²⁴²	2014	18.428	M	F	Ovarian cancer
	E-2013-9 ²⁴³	A. Oza	M	Canada	First	M	13	10	3	0	N/P	Lancet Oncol ²⁴⁴	2015	26.509	M	M	Ovarian cancer
	E-2013-10 ²⁴⁵	F. Sciafani	M	United Kingdom	First	M	10	7	3	0	P	Eur J Cancer ²⁴⁶	2014	5.417	M	M	Colorectal cancer
	E-2013-11 ²⁴⁷	J.C. Soria	M	France	Last	M (= presenter)	17	12	5	0	N/A	Eur J Cancer ²⁴⁸	2014	5.417	F	M	Multiple types of cancer
	E-2013-12 ²⁴⁹	R.E. Coleman	M	United Kingdom	First	F	10	7	3	0	N/P	Lancet Oncol ²⁵⁰	2014	24.690	M	F	Breast cancer

(Continues)

Table 2. abstracts presented at ESMO congresses (Continued)

Presenter			Abstract				Article										
Year	Abstract no.	Name	Sex	Country of origin	Author place	Sex of the last author	No. of authors	No. of male authors	No. of female authors	No. of unknown sex	Study outcome ¹	Journal published	Year	IF	Sex of the first author	Sex of the last author	Subject
2014	E-2013-13 ²⁵¹	J. Ledermann	M	United Kingdom	First	M	10	7	3	0	P	Lancet ²⁵²	2016	47.831	M	M	Ovarian cancer
	E-2013-14 ²⁵³	P. Van Loo	M	United Kingdom	Last	M (= presenter)	10	7	3	0	P	Nat Commun ²⁵⁴	2017	12.353	F	M	Multiple types of cancer
	E-2013-15 ²⁵⁵	J.G. Eriksen	M	Denmark	First	M	10	8	2	0	N	Not (yet) published					Head and neck cancer
	E-2013-16 ²⁵⁶	R. Chlebowski	M	United States	First	F	11	8	3	0	P	JNCI J Natl Cancer J ²⁵⁷	2016	12.589	M	F	Endometrial cancer
	E-2013-17 ²⁵⁸	H.J. de Koning	M	The Netherlands	First	F	9	7	2	0	N	Ann Intern Med ²⁵⁹	2014	17.810	M	F	Lung cancer
	E-2014-1 ²⁶⁰	J.S. Weber	M	United States	First	M	20	17	3	0	P	Lancet Oncol ²⁶¹	2015	26.509	M	M	Melanoma
	E-2014-2 ²⁶²	C. Robert	F	France	First	M	20	14	6	0	P	Lancet Oncol ²⁶³	2015	26.509	M	F	Melanoma
	E-2014-3 ²⁶⁴	G.A. McArthur	M	Australia	First	F	17	12	5	0	P	Lancet Oncol ²⁶⁵	2016	33.900	M	M	Melanoma
	E-2014-4 ²⁶⁶	S. Swain	F	United States	First	M	14	9	5	0	P	New Engl J Med ²⁶⁷	2015	59.558	F	M	Breast cancer
	E-2014-5 ²⁶⁸	J.F. Vansteenkiste	M	Belgium	First	M	20	19	1	0	N	Lancet Oncol ²⁶⁹	2016	33.900	M	M	Lung cancer
2015	E-2014-6 ²⁷⁰	T.S. Mok	M	Hong Kong	First	M	18	14	4	0	N	J Clin Oncol ²⁷¹	2017	26.303	M	M	Lung cancer
	E-2015-1 ²⁷²	M. Sant	F	Italy	First	F	18	8	10	0	P	Eur J Cancer ²⁷³	2015	6.163	F	M	Multiple types of cancer
	E-2015-2 ²⁷⁴	R. Atun	M	United States	First	F	18	12	6	0	P	Lancet Oncol ²⁷⁵	2015	26.509	M	F	Multiple types of cancer
	E-2015-3 ²⁷⁶	P. Sharma	F	United States	First	M	15	12	3	0	P	Eur Urol ²⁷⁷	2017	17.581	M	M	Renal cell carcinoma
	E-2015-4 ²⁷⁸	T. Choueiri	M	United States	First	M	23	17	6	0	P	New Engl J Med ²⁷⁹	2015	59.558	M	M	Renal cell carcinoma
	E-2015-5 ²⁸⁰	C. Vrieling	F	Switzerland	First	M	11	8	3	0	P	JAMA Oncol ²⁸¹	2017	20.871	F	M	Breast cancer
	E-2015-6 ²⁸²	J. Yao	M	United States	First	F	22	18	4	0	P	Lancet ²⁸³	2016	47.831	M	F	Neuroendocrine tumors
	E-2015-7 ²⁸⁴	P. Ruzsiewski	M	France	Second last	M	14	12	2	0	P	New Engl J Med ²⁸⁵	2017	79.260	M	M	Neuroendocrine tumors
	E-2015-8 ²⁸⁶	C. Oude Ophuis	F	The Netherlands	First	M	11	8	3	0	N	Eur J Surg Oncol ²⁸⁷	2016	3.522	F	M	Melanoma
	E-2015-9 ²⁸⁸	R.A. Stahel	M	Switzerland	First	M	20	15	5	0	P	Lancet Respir Med ²⁸⁹	2017	21.466	M	M	Lung cancer
2016	E-2015-10 ²⁹⁰	M.C. Pietanza	F	United States	First	M	15	12	3	0	P	Lancet Oncol ²⁹¹	2017	36.418	M	M	Lung cancer
	E-2015-11 ²⁹²	D. Deamaley	M	United Kingdom	First	F	20	10	10	0	N/P	Lancet Oncol ²⁹³	2016	33.900	M	F	Prostate cancer
	E-2015-12 ²⁹⁴	R. Sullivan	M	United Kingdom	First	M	43	37	6	0	N/A	Lancet Oncol ²⁹⁵	2015	26.509	M	M	Multiple types of cancer
	E-2015-13 ²⁹⁶	M. Carducci	M	United States	First	F	19	16	3	0	P	J Clin Oncol ²⁹⁷	2016	24.008	F	M	Prostate cancer
	E-2015-14 ²⁹⁸	J. Sparano	M	United States	First	M	20	11	9	0	P	New Engl J Med ²⁹⁹	2018	70.670	M	M	Breast cancer
	E-2016-1 ²⁹⁹	G.N. Hortobagyi	M	United States	First	F	20	13	7	0	P	New Engl J Med ³⁰⁰	2016	72.406	M	F	Breast cancer
	E-2016-2 ³⁰¹	A.M. Eggermont	M	France	First	M	19	13	6	0	P	New Engl J Med ³⁰²	2016	72.406	M	M	Melanoma
	E-2016-3 ³⁰³	M. Mirza	M	Denmark	First	F	20	14	6	0	P	New Engl J Med ³⁰⁴	2016	72.406	M	F	Ovarian cancer
	E-2016-4 ³⁰⁵	K. Harrington	M	United Kingdom	First	M	11	6	5	0	P	Lancet Oncol ³⁰⁶	2017	36.418	M	F	Head and neck cancer
	E-2016-5 ³⁰⁷	C. Langer	M	United States	First	F	19	13	6	0	P	Lancet Oncol ³⁰⁸	2016	33.900	M	M	Lung cancer
E-2016-6 ³⁰⁹	M. Reck	M	Germany	First	F	18	9	9	0	P	New Engl J Med ³¹⁰	2016	72.406	M	F	Lung cancer	
E-2016-7 ³¹¹	M. Socinski	M	United States	First	M	20	14	6	0	N	New Engl J Med ³¹²	2017	79.260	M	M	Lung cancer	
E-2016-8 ³¹³	F. Barlesi	M	France	First	M	20	18	2	0	P	Lancet ³¹⁴	2017	53.254	M	M	Lung cancer	
E-2016-9 ³¹⁵	A. Gronchi	M	Italy	First	M	19	15	4	0	P	Lancet Oncol ³¹⁶	2017	36.418	M	M	Soft-tissue sarcoma	
E-2016-10 ³¹⁵	K. Fizazi	M	France	First	M	13	9	4	0	N	Lancet Oncol ³¹⁷	2017	36.418	M	M	Prostate cancer	
E-2016-11 ³¹⁸	T.K. Choueiri	M	United States	First	M	12	10	2	0	P	J Clin Oncol ³¹⁹	2017	26.303	M	M	Renal cell carcinoma	
E-2016-12 ³²⁰	A. Ravaud	M	France	First	M	20	16	3	1	P	New Engl J Med ³²¹	2016	72.406	M	M	Renal cell carcinoma	

(Continues)

Table 2. abstracts presented at ESMO congresses (Continued)

Presenter			Abstract			Article											
Year	Abstract no.	Name	Sex	Country of origin	Author place	Sex of the last presenter author	No. of authors	No. of male authors	No. of female authors	No. of authors unknown sex	Study outcome ¹	Journal published	Year	IF	Sex of the first author	Sex of the last author	Subject
2017	E-2017-1 ³²²	L. Paz-Ares	M	Spain	First	M	20	17	3	0	P	New Engl J Med ³²³	2017	79.260	M	M	Lung cancer
	E-2017-2 ³²⁴	V. Westeel	F	France	First	M	20	17	3	0	N	Not (yet) published					Lung cancer
	E-2017-3 ³²⁵	S. Ramalingam	M	United States	First	M	18	12	6	0	P	New Engl J Med ³²⁶	2018	70.670	M	M	Lung cancer
	E-2017-4 ³²⁷	A. Di Leo	M	Italy	First	M	17	10	7	0	P	J Clin Oncol ³²⁸	2017	26.303	M	M	Breast cancer
	E-2017-5 ³²⁹	S. Gupta	M	India	First	M	20	8	12	0	N	J Clin Oncol ³³⁰	2018	26.303	M	M	Cervical cancer
	E-2017-6 ³³¹	D. Petrylak	M	United States	First	M	20	14	6	0	P	Lancet ³³²	2017	53.254	M	F	Renal cell carcinoma
	E-2017-7 ³³³	B. Escudier	M	France	First	M	20	15	5	0	P	New Engl J Med ³³⁴	2018	70.670	M	M	Renal cell carcinoma
	E-2017-8 ³³⁵	K. Lewis	M	United States	First	M	14	13	0	1	N/P	Lancet Oncol ³³⁶	2018	36.418	M	M	Melanoma
	E-2017-9 ³³⁷	A. Hauschild	M	Germany	First	M	19	12	7	0	P	New Engl J Med ³³⁸	2017	79.260	F	M	Melanoma
	E-2017-10 ³³⁹	J. Weber	M	United States	First	M	20	12	8	0	P	New Engl J Med ³³⁴	2017	79.260	M	M	Melanoma
2018	E-2018-1 ³⁴⁰	P. Schmid	M	United Kingdom	First	F	18	7	11	0	P	New Engl J Med ³⁴¹	2018	70.670	M	F	Breast cancer
	E-2018-2 ³⁴²	M. Cristofanilli	M	United States	First	M	19	9	10	0	P	New Engl J Med ³⁴³	2018	70.670	M	M	Breast cancer
	E-2018-3 ³⁴⁴	F. André	M	France	First	M	20	11	8	1	P	New Engl J Med ³⁴⁵	2019	70.670	M	M	Breast cancer
	E-2018-4 ³⁴⁶	Z. Jiang	M	China	First	M	19	11	4	4	P	Lancet Oncol ³⁴⁷	2019	35.386	M	M	Breast cancer
	E-2018-5 ³⁴⁸	A. Hoyle	M	United Kingdom	First	M	20	18	2	0	P	Not (yet) published					Prostate cancer
	E-2018-6 ³⁴⁹	C. Parker	M	United Kingdom	First	M	19	15	4	0	N	Lancet ³⁵⁰	2018	59.102	M	M	Prostate cancer
	E-2018-7 ³⁵¹	R. Motzer	M	United States	First	M	20	16	3	1	P	New Engl J Med ³⁵²	2019	70.670	M	M	Renal cell carcinoma
	E-2018-8 ³⁵³	K. Moore	F	United States	First	M	19	10	9	0	P	New Engl J Med ³⁵⁴	2018	70.670	F	M	Ovarian cancer
	E-2018-9 ³⁵⁵	B. Burtness	F	United States	First	M	20	12	7	1	P	Not (yet) published					Head and neck cancer
	E-2018-10 ³⁵⁶	H. Mehanna	M	United Kingdom	First	F	20	14	6	0	N	Lancet ³⁵⁷	2019	59.102	M	F	Oropharyngeal cancer
Total	N = 132	C. Zhou	M	China	First	M	18	8	4	6	P	Lancet Respir Med ³⁵⁹	2019	22.992	M	M	Lung cancer
			F: N = 27			F: N = 26	1,856	1,340	500	16	P	N = 125			F: N = 23	F: N = 27	

¹Abstracts presented at presidential symposia of ESMO Congresses (2006, 2008, 2010, 2012, 2014, 2006–2018), and ESMO/ECCO conferences (2009, 2013, 2015). Presenters were last abstract authors in E-2011-12, E-2012-7, E-2013-11, and E-2013-14, and therefore, presenter's and last abstract author's sex are similar. For papers published in 2019, journal impact factors of 2018 were used.

Abbreviations: ECCO, European Cancer Organization; ESMO, European Society for Medical Oncology; F, female; IF, impact factor; M, male; N, negative; N/A, not applicable; no., number; N/P, outcome did not reach significance or endpoint, but did show improvement/benefit or reached some of the outcomes; P, positive.

Data availability

The data that support the findings of our study are available from the corresponding author upon reasonable request.

Results

Presenters

Data of 166 consecutive abstracts presented at plenary sessions of ASCO Annual Meetings from 2011 and at ESMO Congresses from 2008 were collected. Included abstracts of the plenary sessions of ASCO Annual Meetings between 2011 and 2018 ($n = 34$) and of the presidential sessions of ESMO conferences between 2008 and 2018 ($n = 132$) are shown in Tables 1 and 2, respectively. References of all of these abstracts and subsequently published papers can be found in the Supplementary Material.

Of all 166 abstracts, 35 (21%) were presented by a woman. Although the proportion of female presenters has decreased since 2015–2016 (Fig. 1), the distribution of female and male contribution to presenters was not different over the years ($p = 0.699$), neither was a trend observed in contribution of both sexes over time ($p = 0.350$).

The majority of the presenters originated from Europe ($n = 90$, 54%), followed by Northern America ($n = 65$, 39%), Asia ($n = 9$, 5%) and Oceania ($n = 2$, 1%). All female presenters came from Northern America ($n = 17$) or Europe ($n = 18$). The share of women of all Northern American and European presenters was 26 and 20%, respectively. Per country, 17 of 62 (27%) American, 5 of 29 (17%) British, 1 of 6 (17%) Belgian, 2 of 17 (12%) French, 6 of 13 (46%) Dutch, 2 of 4 (50%) Swiss, 1 of 5 (20%) Italian presenters and the only Austrian presenter were female.

Almost a quarter of the studies presented by a female researcher ($n = 35$) concerned breast cancer ($n = 8$, 23%), lung cancer ($n = 3$, 9%), followed by ovarian cancer, colorectal cancer and multiple types of cancer (all: $n = 4$, 11%). Other subjects are




Figure 1. Proportion of female presenters and abstract authors over time at plenary sessions of American Society of Clinical Oncology (ASCO) Annual Meetings and European Society for Medical Oncology (ESMO) Congresses. Results of 2008–2010 is based on ESMO abstracts solely. Abstract authors with unknown sex ($n = 19$) are not displayed.

shown in Tables 1 and 2. Overall, 26% of the presentations about breast cancer, 44% about ovarian cancer, 29% about colorectal cancer and 17% about lung cancer were presented by a woman.

Study outcomes were most often positive ($n = 119$, 71%), while 33 (20%) had negative outcomes and 14 (8%) neither positive nor negative (N/P), or nonapplicable (N/A). Outcomes were positive, negative and N/P or N/A in 71, 23 and 6% of the 35 studies presented by a female researcher, and 72, 19 and 9% of 131 abstracts with male presenters, respectively. The outcomes of presented abstracts did not differ between male and female presenters ($p = 0.746$). Presenter's sex was not associated with study outcome ($p = 0.815$).

Abstract authors

Figure 1 shows the overall proportion of female presenters and abstract authors. Of all authors of the presented abstracts ($n = 2,425$), 679 (28%) were female, 1,728 (71%) were male and sex was unknown in 19 (1%) authors. The distribution of sex of abstract authors differed statistically significantly over the years ($p = 0.046$), and a positive trend was observed in contribution of female authors over time ($p = 0.007$). The number of female authors was higher in abstracts with a female presenter (34%) compared to abstracts with a male presenter (26%; $p = 0.001$).

Overall, contribution of women to last abstract authorship was 20% ($n = 33$). Last abstracts' authors were female in 9/35 (26%) of the studies presented by a woman and in 23/131 (18%) of studies presented by a male researcher ($p = 0.277$).

Sex of the last abstract author was not associated with study outcomes ($p = 0.433$).

Subsequently published papers

The majority of the 166 presented abstracts were subsequently published in an international journal ($n = 156$, 94%). In 56 (36%) of these 156 papers, either the first or last author was a woman. Female researchers were involved as first author in 29 (19%) and last author in 32 (21%) articles.

A total of 30/35 (86%) abstracts presented by a woman were published as article, which was statistically significantly less than the 126/131 (96%) abstracts with a male presenter that resulted in a paper ($p = 0.021$). In 4/30 (13%) articles, the female presenter of the abstract was not involved as first, second or last author, and the first authors of these papers were all males (A-2017-1, E-2011-4, E-2013-8 and E-2015-10; Tables 1 and 2). In 3/126 (2%) published papers with a male abstract presenter, the presenter was not first, second or last author of the article, and all the first authors were other males (E-2010-2, E-2011-1, E-2017-1; Table 2).

Median IF of journals of papers with a female first author was 20.3 (interquartile range [IQR], 8.4, 53.4), which was lower than of papers with a male first author (median IF 35.4 [IQR, 20.5, 59.1]; $p = 0.046$). Sex of the presenter, last abstract author, or last author of the manuscript were not associated with IF of journals of subsequently published papers ($p = 0.101$, $p = 0.864$ and $p = 0.922$, respectively).




Figure 2. Distribution of sex in both American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) abstract presenters and authors.

ASCO vs. ESMO

Figure 2 shows the sex distribution of abstract presenters in both ASCO and ESMO conferences. The distribution of sex of presenters did not differ between ASCO and ESMO ($p = 0.756$), but the proportion of female authors in ASCO abstracts (32%) was significantly higher compared to those of ESMO (27%; $p = 0.048$).

When analyzing the meetings separately, we found a statistically significant positive trend in female contribution observed in ESMO abstract authors ($p = 0.014$), which was not found in ASCO abstract authors ($p = 0.544$). This trend over time in female contribution was not identified in ASCO and ESMO presenters ($p = 0.350$ and $p = 0.656$).

Discussion

Although gender differences have been acknowledged in medical research,^{1,2,5,6,8,9} this is the first study to describe the gender gap in contribution to research presentations at the two largest oncological conferences in the world. Of all oncological studies presented at the main sessions of the past 8 ASCO Annual Meetings and 12 ESMO Congresses, the number of female presenters did not reach a quarter. In subsequently published papers, the share of female first and last authors was even smaller. The gender gap appears to be more prominent in oncological research than in clinical practice, because nearly half of the hematology–oncology fellowship trainees in the United States,^{19,20} more than half of

medical oncologists in several European countries²¹ and 37% of ASCO and 41% of ESMO members are female.²² Moreover, we found an association between sex of first author of subsequently published manuscripts and the journal's IF. Although IFs of these journals were all relatively high, which is not surprising given that these studies were presented at the most important sessions of the conferences, this corresponds with findings about the underrepresentation of female authors in high-impact journals.^{23,24}

The lack of women presenting at oncological conferences is in line with the trend of gender differences in other research areas, where males numerically outweigh females, despite an increase in women entering scientific careers.^{1,2,9,25,26} The number of publications by male researchers remains significantly higher than those by females, as is also seen in authorships of oncological publications.^{10,12} In our study, we found an overall female contribution to abstract authorships of 27–31%, with an increase of female contribution as abstract authors over time. However, this rise was not observed among female presenters at both conferences. Although it was not a statistically significant trend, the proportion of female presenters since 2015 appears to be shrinking rather than increasing and is therefore worrisome (Fig. 1).

Over the span of their academic career, publication productivity of women increases at a later stage of their career compared to men.^{4,27} While the publication productivity of female researchers exceeded those of male researchers toward

the end of their careers, that is, after 27 years of service, most leadership appointments occurred before the 20th year of service.⁴ Because productivity is an important factor in the selection of leaders, this could be one of the causes for the underrepresentation of women in leading positions. As not only the content of the abstract, but also past productivity and leadership positions may influence the selection of presenters for the most important sessions of ASCO and ESMO conferences, this could partly explain the underrepresentation of female presenters in these sessions as well.

Interpretation of data on gender disparities, including our data, may be hindered by a Simpson's paradox, as described earlier.^{28,29} This paradox implies that an apparent association can actually be a result of a third dependent factor. For example, a finding that female researchers received requested grants less often than men was biased because women applied more often for grants in more competitive research fields.²⁸ More specifically, our findings could be the result of self-selection, in case that less women chose to submit an abstract to ASCO and ESMO or indicated they wanted to give a poster presentation rather than an oral presentation. In other scientific fields, gender differences in presentations at a congress have been identified as a result of self-selection.^{14,17,30} For example, in biology women were asked less often as an invited speaker, even when adjusted for career stage, but also declined invitations more often than men.¹⁷ Similarly, at an anthropology conference, women appeared to ask for oral presentations less frequently than men, resulting in significantly more poster and less oral presentations than male researchers.³⁰ At a conference on evolutionary biology, women presented for relatively shorter duration compared to men despite a fifty-fifty attendance, mainly because men requested longer presentations more often.¹⁴ Unfortunately, we did not have information about the number of submitted abstracts to ASCO and ESMO or whether the persons who submitted the abstracts requested a presentation or a poster. However, the findings in other fields highlight the possibility of self-selection as a cause for the gender differences that we found and emphasize the need for women to increase their assertiveness in order to narrow the gender gap.

Gender, in contrast to sex, is a social construct of characteristics as norms and roles of and between women and men, instead of a "biological given" that is beyond our control.^{31,32} To open up avenues for change, possible consequences of gender and its behavior-based cause must be underlined.³³ This starts with recognizing the gender gap³⁴ and efforts to change perceptions of inequality associated with gender, for example, on competence^{32,35} and meritocracy.^{24,27,35} Possible solutions beside acknowledgement of these biases that could bridge the gap in (oncological) research and level the playing field for both sexes may include

encouragement of self-promotion in female researchers, and implementation of guidelines that concern gender equality.³³ For example, this could start with involving more women in the organizing committees of conferences, because this has been positively associated with female representation at conferences.^{13,30} Second, the abstract assessment process could be changed by appraising the abstracts without information on the presenter's or authors' sexes or names. Moreover, female presenters could inspire and encourage female young researchers to follow their example. Finally, because all the female presenters came from the USA or Europe in our study, there should be greater awareness of the gender gap among researchers originating from other parts of the world.

Not only do gender gaps potentially disadvantage women, they could also impair patients outcomes and science.¹ In oncological research, for example, several sex-based differences in the treatment and outcomes of cancer patients have been explored and revealed important issues in, for example, drug responses and toxicity.^{36–38} The presence of a female author in a study has been positively associated with the likelihood of the exploration and analysis of these sex-based differences.^{39,40} Diversity in sex of researchers could therefore also contribute to a more diverse perception of science, possibly contributing to favorable outcomes for patients in the end, especially in the light of recent findings in sex-based differences in oncology.³⁶

Our study has some limitations. We only included abstracts presented at the most important sessions of two main oncological conferences in the world, therefore we do not know the gender balance in abstracts presented in other sessions or at other conferences. Moreover, a considerable part of the abstracts presented in 2018 were not yet published, which could have resulted in a bias. Lastly, we did not have data on the sex distribution of attendees at the conferences, or the proportion of females that participate in oncological research worldwide to compare this to the share of female presenters and abstract authors.

In conclusion, the share of female presenters at the main sessions of ASCO Annual Meetings and ESMO Congresses is only 21%, and 28% in authorships of these presented abstracts. Greater visibility of women at these large oncological conferences should be encouraged to allow acknowledgement for their research and opportunities for their academic career, as well as positively drive heterogeneity in research through diversity in sex of researchers.

Acknowledgements

The idea to perform this study was launched by participants of the European Society for Medical Oncology Leaders Generation Program 2018. We would like to thank the ESMO Women for Oncology Committee for their support to pursue this idea.

References

1. Rotenstein LS, Jena AB. Lost Taussigs—the consequences of gender discrimination in medicine. *N Engl J Med* 2018;378:2255–7. <https://doi.org/10.1056/NEJMp1802228>.
2. Shannon G, Jansen M, Williams K, et al. Gender equality in science, medicine, and global health:

- where are we at and why does it matter? *Lancet* 2019;393:560–9. [https://doi.org/10.1016/S0140-6736\(18\)33135-0](https://doi.org/10.1016/S0140-6736(18)33135-0).
3. Hofstädter-Thalmann E, Dafni U, Allen T, et al. Report on the status of women occupying leadership roles in oncology. *ESMO Open* 2018;3:e000423.
 4. Reed DA, Enders F, Lindor R, et al. Gender differences in academic productivity and leadership appointments of physicians throughout academic careers. *Acad Med* 2011;86:43–7.
 5. Reeder-Hayes K, Filip E, Patt D, et al. Women in oncology: progress, challenges, and keys to success. *Am Soc Clin Oncol Educ B* 2013;33: 448–55.
 6. Steinberg JJ, Skae C, Sampson B. Gender gap, disparity, and inequality in peer review. *Lancet* 2018; 391:2602–3. [https://doi.org/10.1016/S0140-6736\(18\)31141-3](https://doi.org/10.1016/S0140-6736(18)31141-3).
 7. Nature's sexism. *Nature* 2012;491:495.
 8. Larivière V, Ni C, Gingras Y, et al. Bibliometrics: global gender disparities in science. *Nature* 2013; 504:211–3. <https://doi.org/10.1038/504211a>.
 9. Lundine J, Bourgeault IL, Clark J, et al. The gendered system of academic publishing. *Lancet* 2018;391:1754–6.
 10. Van LT, Wouters P. Analysis of gender distribution in Dutch oncology research. Leiden, The Netherlands: Centre for Science and Technology Studies, 2018. Available from: https://athenasangels.nl/images/Analysis_of_Gender_in_Dutch_Oncology_research.pdf.
 11. González-Álvarez J, Cervera-Crespo T. Research production in high-impact journals of contemporary neuroscience: a gender analysis. *J Informet* 2017;11:232–43. <https://doi.org/10.1016/j.joi.2016.12.007>.
 12. Sun GH, Moloci NM, Schmidt K, et al. Representation of women as authors of collaborative cancer clinical trials. *JAMA Intern Med* 2014;174:806–8.
 13. Casadevall A, Handelsman J. The presence of female conveners correlates with a higher proportion of female speakers at scientific symposia. *MBio* 2014;5:1–4.
 14. Jones TM, Fanson KV, Lanfear R, et al. Gender differences in conference presentations: a consequence of self-selection? *PeerJ* 2014;2:e627. Available from: <https://peerj.com/articles/627>.
 15. Klein RS, Voskuhl R, Segal BM, et al. Speaking out about gender imbalance in invited speakers improves diversity. *Nat Immunol* 2017;18:475–8.
 16. Pell AN. Fixing the leaky pipeline: women scientists in academia. *J Anim Sci* 1996;74:2843–8.
 17. Schroeder J, Dugdale HL, Radersma R, et al. Fewer invited talks by women in evolutionary biology symposia. *J Evol Biol* 2013;26:2063–9.
 18. Sleeman KE, Koffman J, Higginson JJ. Leaky pipeline, gender bias, self-selection or all three? A quantitative analysis of gender balance at an international palliative care research conference. *BMJ Support Palliat Care* 2019;9:146–8.
 19. Association of American Medical Colleges. *Active physicians by age and specialty. Work. Reports* 2017; Table 1.3. Number and percentage of active physician. Association of American Medical Colleges. Available from: <https://www.aamc.org/data/-workforce/reports/492560/1-3-chart.html> (accessed February 21, 2019).
 20. Green AK, Barrow B, Bach PB. Female representation among US National Comprehensive Cancer Network guideline panel members. *Lancet Oncol* 2019;20:327–9.
 21. de Azambuja E, Ameye L, Paesmans M, et al. The landscape of medical oncology in Europe by 2020. *Ann Oncol* 2014;25:525–82.
 22. Banerjee S, Dafni U, Allen T, et al. Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. *ESMO Open* 2018;3:1–10.
 23. Filardo G, Graca B Da, Sass DM, et al. Trends and comparison of female first authorship in high impact medical journals: Observational study (1994–2014). *BMJ* 2016;352.
 24. Nielsen MW. Gender inequality and research performance: moving beyond individual-meritocratic explanations of academic advancement. *Stud High Educ* 2016;41:2044–60. <https://doi.org/10.1080/03075079.2015.1007945>.
 25. Maliniak D, Powers RM, Walter BF. The Gender Citation Gap in International Relations. *IntOrgan* 2013;67:889–922.
 26. Clark J, Zuccala E, Horton R. Women in science, medicine, and global health: call for papers. *Lancet* 2017;390:2423–4. [https://doi.org/10.1016/S0140-6736\(17\)32903-3](https://doi.org/10.1016/S0140-6736(17)32903-3).
 27. van den Brink M, Benschop Y. Gender practices in the construction of academic excellence: sheep with five legs. *Organization* 2012;19:507–24.
 28. Albers CJ. Dutch research funding, gender bias, and Simpson's paradox. *Proc Natl Acad Sci* 2015; 112:E6828–9.
 29. Bickel PJ, Hammel EA, O'Connell JW. Sex bias in graduate admissions: data from Berkeley. *Science* 1975;187:398–404. <https://doi.org/10.1126/science.187.4175.398>.
 30. Isbell LA, Young TP, Harcourt AH. Stag parties linger: continued gender bias in a female-rich scientific discipline. *PLoS One* 2012;7:2–5.
 31. World Health Organisation. *Gender, equity and human rights*. WHO, 2016. Available from: <http://www.who.int/gender-equity-rights/understanding/gender-definition/en/>. (accessed July 2, 2018).
 32. Correll SJ. Gender and the career choice process: the role of biased self-assessments. *Am J Sociol* 2002;106:1691–730.
 33. Kang SK, Kaplan S. Working toward gender diversity and inclusion in medicine: myths and solutions. *Lancet* 2019;393:579–86.
 34. Rabinowitz LG. Recognizing blind spots—a remedy for gender bias in medicine? *N Engl J Med* 2018;378:2253–5. <https://doi.org/10.1056/NEJMp1802228>.
 35. Nielsen MW. Limits to meritocracy? Gender in academic recruitment and promotion processes. *Sci Public Policy* 2016;43:386–99.
 36. Özdemir BC, Csajka C, Dotto GP, et al. Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology. *J Clin Oncol* 2018;36: 2680–3.
 37. Cristina V, Mahachie J, Mauer M, et al. Association of patient sex with chemotherapy-related toxic effects: a retrospective analysis of the PETACC-3 trial conducted by the EORTC gastrointestinal group. *JAMA Oncol* 2018;4: 1003–6.
 38. Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. *Lancet Oncol* 2018;19:737–46. [https://doi.org/10.1016/S1470-2045\(18\)30261-4](https://doi.org/10.1016/S1470-2045(18)30261-4).
 39. Nielsen W, Alegria S, Börjeson L, et al. Opinion: gender diversity leads to better science. *Proc Natl Acad Sci* 2017;114:E2796–6. <https://doi.org/10.1073/pnas.1703146114>.
 40. Sugimoto CR, Ahn Y-Y, Smith E, et al. Factors affecting sex-related reporting in medical research: a cross-disciplinary bibliometric analysis. *Lancet* 2019;393:550–9. [https://doi.org/10.1016/S0140-6736\(18\)32995-7](https://doi.org/10.1016/S0140-6736(18)32995-7).

6:43 PM DEC 01, 2022

THE MOMENT YOUR GUT INSTINCT
WAS BACKED BY SCIENTIFIC
RESULTS_



THE DIFFERENCE OF BREAKTHROUGH MOMENTS

WITH COMPLETE SOLUTIONS FOR GROUNDBREAKING DISCOVERIES FROM A TRUSTED PARTNER.

Your next breakthrough could be closer than you imagine, especially with the right resources to help you advance your research. At BD, we are dedicated to helping you get the data you need, when, where and how you need it. Our integrated solutions in instrumentation, software and reagents are optimized to work together to bring you closer to your next breakthrough moment. And you can depend on us for world-class training, service and support to help you get the most from the results your research depends on. Discover a range of optimized solutions that open endless possibilities for your future research. **Discover the new BD.**

Learn how you can advance your research >

